Genitourinary Lesions Due to Monkeypox.

BACKGROUND: Since May 2022, 31 000 cases of monkeypox infection have been reported in nonendemic areas. OBJECTIVE: To describe a series of cases of monkeypox with genitourinary involvement. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective observational study of men diagnosed with monkeypox disease with genitourinary involvement. RESULTS AND LIMITATIONS: A total of 14 patients were recruited. The median age was 42 yr. Of these patients, 43% sought a consultation for genitourinary symptomatology, and 71% had engaged in sex with other men. Eight patients (57%) were positive for human immunodeficiency virus, one diagnosed synchronously; the remainder had a median CD4 count of 663/µl. Six patients (43%) had a different sexually transmitted disease. Penile oedema was present in 43% of patients and two patients required surgical exploration. CONCLUSIONS: Genitourinary involvement is frequent in monkeypox disease and is often the reason for the consultation visit. PATIENTS SUMMARY: In this report we looked at how monkeypox disease can affect the genitourinary area, causing swelling of the penis or skin lesions.

Efficacy, tolerance and predictors of response to the treatment with hyperbaric oxygen therapy for patients with hemorrhagic radiation cystitis.

OBJECTIVES: The aim was to study the efficacy and tolerance in patients with haemorrhagic radiation-induced cystitis (HRC) treated with hyperbaric oxygen therapy (HOT) and analyze which factors were related to the response to the treatment. MATERIAL AND METHODS: We performed a retrospective cohort study of patients treated with HOT for HRC symptoms in a provincial referral centre from 2010 to 2020. We evaluated clinical response to treatment, number of hospitalizations due to HRC and subjective response using the PGI-I questionnaire. RESULTS: We treated 52 patients, with a median of 30 sessions, during 6 months and 40 months (6-68 months) of follow-up. 69.2%of patients responded completely and 21,2% partially. The 53.2% of patients improved before the first 10 sessions. Reduction of hospitalizations/per year due to haematuria from 2.8 to 1.1 (p=0,001). The 73,5% of patients stated that they were "very much better" or "much better" after treatment. During the follow-up, 15.4% of patients had recurrence of HRC. 9.6% of the patients required salvage cystectomy. The patients with a highest RTOG-EORTC scale had more risk to still with symptoms (OR 3.01 (IC95 1.48 - 6.16). All patients were able to complete the proposed treatment plan with good tolerance to HOT. CONCLUSIONS: These results show the clinical benefit of HOT in the treatment of HRC, with a reduction of the number of hospitalizations and a subjective improvement.

Efficacy, tolerance and predictors of response to the treatment with hyperbaric oxygen therapy for patients with hemorrhagic radiation cystitis

Objectives: The aim was to study the efficacy and tolerance in patients with haemorrhagic radiation-induced cystitis (HRC)treated with hyperbaric oxygen therapy (HOT) and analyze which factors were related to the response to the treatment.Material and methods: We performed a retrospective cohort study of patients treated with HOT for HRC symptoms in a provincial referral centre from 2010 to 2020. We evaluated clinical response to treatment, number of hospitalizations due to HRC andsubjective response using the PGI-I questionnaire.Results: We treated 52 patients, with a median of 30 sessions, during 6 months and 40 months (6-68 months) of follow-up. 69.2%of patients responded completely and 21,2% partially. The 53.2% of patients improved before the first 10 sessions. Reduction ofhospitalizations/per year due to haematuria from 2.8 to 1.1 (p=0,001). The 73,5% of patients stated that they were “very muchbetter” or “much better” after treatment. During the follow-up, 15.4% of patients had recurrence of HRC. 9.6% of the patientsrequired salvage cystectomy. The patients with a highest RTOG-EORTC scale had more risk to still with symptoms (OR 3.01(IC95 1.48 – 6.16). All patients were able to complete the proposed treatment plan with good tolerance to HOT.Conclusions: These results show the clinical benefit of HOT in the treatment of HRC, with a reduction of the number of hospitalizations and a subjective improvement. (AU)

Objetivo: conocer eficacia y tolerancia de la hiperoxigemia en cámara hiperbárica (THO) en pacientes con cistitis rádica hemorrágica (CRH) y analizar factores asociadosa respuesta al tratamiento.Material y métodos: estudio de cohorte retrospectivode pacientes tratados mediante THO por CRH en centro dereferencia entre 2010 y 2020. Evaluamos respuesta clínicade la hematuria, número de ingresos hospitalarios por CRHy satisfacción subjetiva mediante cuestionario PGI-I.Resultados: tratamos 52 pacientes, mediana de 30 sesiones con 6 meses de tratamiento y 40 meses (6-68 meses)de seguimiento. El 69,2% obtuvo respuesta completa y el21,2% respuesta parcial. El 53,2% mejoró antes de las 10primeras sesiones. La reducción de los ingresos hospitalarios/año por hematuria fue de 2,8 a 1,1 (p=0,001). El 73,5%de pacientes señaló encontrarse “Mucho mejor” o “un pocomejor” tras el tratamiento. Durante el seguimiento, el15,4% presentaron recurrencia de hematuria. Del total dela serie, 9,6% de pacientes precisó cistectomía de rescate.El análisis de supervivencia mostró una asociación entre eltiempo de desaparición de la hematuria y la clasificación dela escala RTOG-EORTC (OR 3,01 (IC95 1,48-6,16). Todoslos pacientes pudieron finalizar el plan de tratamiento propuesto con buena tolerancia a la THO.Conclusiones: la THO muestra beneficio clínico enel tratamiento de la CRH, redujo los episodios de hospitalización por hematuria y mejoró la calidad de vida de lospacientes, con buena tolerancia al tratamiento. (AU)

[Metabolic alterations and stones in patients with orthotopic ileal diversions. Case description.] / Alteraciones metabólicas y litiasis en pacientes con derivación ileal ortotópica. A propósito de un caso.

OBJECTIVE: Bacterial presence, anatomic anomalies and metabolic alterations increase the risk of stone formation in patients with neobladders. These patients sometimes require medical or surgical procedures. The aim of the current work is to analyze those alterations and medical treatment associated to it. METHODS: A case of a 66 yo male who had undergone a cystectomy with neobladder 3 years ago. Currently present with a staghorn stone on the right kidney. Past medical history of stone formation as well as double J calcification. RESULTS: The combination of medical and surgical treatment for stone was performed. Medical therapy will allow prevention of new stones. CONCLUSIONS: Metabolic and chronic infections in patients with neobladders treated should decreased the new stone formation in patients with neobladders.

OBJETIVO: La colonización bacteriana, las alteraciones anatómicas y las anomalías metabólicas aumentan el riesgo de litiasis en los pacientes con neovejiga, precisando en muchas ocasiones de un abordaje médico y quirúrgico complejo. El objetivo del trabajo es analizar dichas alteraciones y el tratamiento médico de las mismas. MÉTODOS: Se presenta el caso de un varón de 66 años con antecedente de cistectomía más derivación ortotópica desde hace tres años, el cual presenta litiasis coraliforme en riñón derecho. Antecedentes de varias litiasis, así como calcificación de doble J. RESULTADO: Mediante la combinación de tratamientos médicos y quirúrgicos se tratan las litiasis del paciente, siendo especialmente importante el manejo médico en la prevención de futuros eventos litiásicos. CONCLUSIONES: Diagnosticar y tratar las alteraciones metabólicas y las infecciones crónicas en pacientes con neovejiga puede reducir la aparición de litiasis en los pacientes con neovejiga.

Alteraciones metabólicas y litiasis en pacientes con derivación ileal ortotópica. A propósito de un caso / Metabolic alterations and lithiasis in patients with orthotopic ileal diversion. About a case

Objetivo: La colonización bacteriana, lasalteraciones anatómicas y las anomalías metabólicas aumentan el riesgo de litiasis en los pacientes con neovejiga,precisando en muchas ocasiones de un abordaje médicoy quirúrgico complejo. El objetivo del trabajo es analizardichas alteraciones y el tratamiento médico de las mismas.Métodos: Se presenta el caso de un varón de 66 añoscon antecedente de cistectomía más derivación ortotópicadesde hace tres años, el cual presenta litiasis coraliformeen riñón derecho. Antecedentes de varias litiasis, así comocalcificación de doble J. Resultado: Mediante la combinación de tratamientosmédicos y quirúrgicos se tratan las litiasis del paciente,siendo especialmente importante el manejo médico en laprevención de futuros eventos litiásicos.Conclusiones: Diagnosticar y tratar las alteracionesmetabólicas y las infecciones crónicas en pacientes conneovejiga puede reducir la aparición de litiasis en los pacientes con neovejiga.(AU)

Objetive: Bacterial presence, anatomicanomalies and metabolic alterations increase the risk ofstone formation in patients with neobladders. These patients sometimes require medical or surgical procedures.The aim of the current work is to analyze those alterationsand medical treatment associated to it.Methods: A case of a 66 yo male who had undergonea cystectomy with neobladder 3 years ago. Currently present with a staghorn stone on the right kidney. Past medicalhistory of stone formation as well as double J calcification.Results: The combination of medical and surgical treatment for stone was performed. Medical therapy will allowprevention of new stones.Conclusions: Metabolic and chronic infections in patients with neobladders treated should decreased the newstone formation in patients with neobladders.(AU)

Transurethral Drainage of Prostatic Abscess Using 120 W Holmium Laser Technology.

Introduction: Prostatic abscess is an infrequent but serious pathology that could be treated by ultrasound-guided puncture, transurethral resection, or open surgery. Case Report: We present a case of a 72-year-old male with a 3x5 cm prostatic abscess in the right lobe showed in abdominal computed tomography (CT). In the blood test, he presented coagulopathy. Urgent transurethral drainage by holmium laser was decided to be performed. It started with incision and opening of the right prostatic lobe with an energy of 1.2 J and a frequency of 20 Hz with a total power of 24 W. A 550-micron fiber was used for this technique. Coagulation of the area was performed with a power of 20 W. The postoperative course was uneventful. Conclusion: The holmium laser appears to be an effective alternative in the treatment of this pathology in patients with coagulation disorders by providing adequate hemostatic control.

Terapia de deprivación androgénica en cáncer de próstata avanzado. Estudio multicéntrico / Androgen deprivation therapy in advanced prostate cancer. Multicenter study

OBJETIVO: El cáncer de próstata (CP) avanzado es una entidad frecuente. Los objetivos de este trabajo son la presentación de una serie de pacientes con CP en tratamiento con Terapia de Deprivación Androgénica (TDA) en práctica clínica habitual y la determinación de parámetros asociados al desarrollo de resistencia a la castración (CPRC). MATERIAL Y MÉTODOS: Estudio multicéntrico, observacional, retrospectivo que analiza pacientes tratados con TDA desde enero 2016 hasta enero 2017. Análisis descriptivo de las variables clínicas más relevantes, análisis univariante y supervivencia libre de progresión mediante test Kaplan-Meier. RESULTADOS: Muestra 952 pacientes. Al diagnóstico del CP edad mediana 74 años. Mediana de PSA al diagnóstico de CP 23 ng/ml, al inicio TDA 20,2 ng/ml. El 80,2% de pacientes tenían biopsia al diagnóstico del CP: 28,2% grado pronóstico Gleason grupo 1, 38,7% grados 2 y 3 y 33,1% grados 4 y 5. Tratamiento inicial del CP: 75,9% TDA, prostatectomía radical 8,4% y radioterapia 15,1%. De los 952 pacientes, 281 (29,6%) cumplían criterios de CPRC. En este grupo el 21,7% alcanzó PSA indetectable (<0,1 ng/ml) con la TDA 20,2 frente al grupo no CPRC en el que lo alcanzaron el 59,9%. Encontramos mayor probabilidad de progresión a CPRC en pacientes con PSA al diagnóstico de CP > 30 ng/ml (p = 0,000, OR 2,78), grado pronóstico Gleason grupos 4-5 (p = 0,000, OR 2,33) y en aquellos que no alcanzan PSA indetectable tras TDA (p < 0,01, OR 3,32) variables que se relacionan con los tiempos de progresión a CPRC y especialmente al estadio metastásico. CONCLUSIONES: Se presenta una serie de pacientes CP avanzado en tratamiento con TDA que muestra heterogeneidad de características y de manejo según práctica clínica habitual. En nuestra serie el PSA elevado al diagnóstico, histología desfavorable y no alcanzar un PSA< 0,1 ng/ml tras la TDA se presentan como indicadores de progresión a estadio CPRC

OBJECTIVES: Advanced prostate cancer (PC) is a frequent entity. The objectives of this paper are the presentation of a sample of patients with PC undergoing treatment with androgen deprivation therapy (ADT) in usual clinical practice and the determination of parameters associated with the development of resistance to castration (CRPC). MATERIAL AND METHODS: Multicenter, observational, retrospective study that analyzes patients treated with ADT from January 2016 to January 2017. Descriptive analysis of the most relevant clinical variables and univariante analysis and progression times by Kaplan-Meier test. RESULTS: Sample of 952 patients. At PC diagnosis median age 74 years. Median PSA at PC diagnosis 23 ng/ml, when begining ADT 20.2 ng/ml. 80.2% of patients were biopsied at PC diagnosis: 28.2% Gleason score group 1, 38.7% groups 2 and 3 and 33.1% groups 4 and 5. Initial treatment of PC: 75.9% ADT, radical prostatectomy 8.4% and radiotherapy 15.1%. Of the 952 patients, 281 (29.6%) fulfilled CRPC criteria. In this group 21.7% achieved undetectable PSA (< 0.1 ng/ml) with ADT compared to the non-CRPC group in which it was 59.9%. Increased probability of progression to CRPC in: PSA >30ng/ml at PC diagnosis (p = 0.000, OR 2.78), Gleason score group 4-5 (p = 0.000, OR 2.33), and not to reach undetectable PSA after ADT (p < 0.001, OR 3.32). The initial ADT group presents progression to metastatic CRPC more rapidly in unfavourable histology and when not reached undetectable PSA after ADT. CONCLUSIONS: We present a sample of patients with advanced PC in treatment with ADT that shows heterogeneity in usual clinical practice. In our sample, elevated PSA at PC diagnosis, unfavorable histology and failure to achieve a PSA <0.1ng/ml after ADT is presented as an indicator of progression to the CRPC stage

[Androgen deprivation therapy in advanced prostate cancer. Multicenter study.] / Terapia de deprivación androgénica en cáncer de próstata avanzado. Estudio multicéntrico.

OBJECTIVES: Advanced prostate cancer (PC) is a frequent entity. The objectives of this paper are the presentation of a sample of patients with PC undergoing treatment with androgen deprivation therapy (ADT) in usual clinical practice and the determination of parameters associated with the development of resistance to castration (CRPC). MATERIAL AND METHODS: Multicenter, observational, retrospective study that analyzes patients treated with ADT from January 2016 to January 2017. Descriptive analysis of the most relevant clinical variables and univariante analysis and progression times by Kaplan-Meier test. RESULTS: Sample of 952 patients. At PC diagnosis median age 74 years. Median PSA at PC diagnosis 23 ng/ml, when begining ADT 20.2 ng/ml. 80.2% of patients were biopsied at PC diagnosis: 28.2% Gleason score group 1, 38.7% groups 2 and 3 and 33.1% groups 4 and 5. Initial treatment of PC: 75.9% ADT, radical prostatectomy 8.4% and radiotherapy 15.1%. Of the 952 patients, 281 (29.6%) fulfilled CRPC criteria.In this group 21.7% achieved undetectable PSA (group in which it was 59.9%. Increased probability of progression to CRPC in: PSA >30ng/ml at PC diagnosis (p=0.000, OR 2.78), Gleason score group 4-5 (p=0.000, OR 2.33), and not to reach undetectable PSA after ADT (p <0.001, OR 3.32). The initial ADT group presents progression to metastatic CRPC more rapidly in unfavourable histology and when not reached undetectable PSA after ADT. CONCLUSIONS: We present a sample of patients with advanced PC in treatment with ADT that shows heterogeneity in usual clinical practice. In our sample, elevated PSA at PC diagnosis, unfavorable histology and failure to achieve a PSA<0.1 ng/ml after ADT is presented as an indicator of progression to the CRPC stage.

OBJETIVO: El cáncer de próstata (CP) avanzado es una entidad frecuente. Los objetivos de este trabajo son la presentación de una serie de pacientes con CP en tratamiento con Terapia de Deprivación Androgénica (TDA) en práctica clínica habitual y la determinación de parámetros asociados al desarrollo de resistencia a la castración (CPRC).MATERIAL Y MÉTODOS: Estudio multicéntrico,  observacional, retrospectivo que analiza pacientes tratados con TDA desde enero 2016 hasta enero 2017. Análisis descriptivo de las variables clínicas más relevantes, análisis univariante y supervivencia libre de progresión mediante test Kaplan-Meier. RESULTADOS: Muestra 952 pacientes. Al diagnóstico del CP edad mediana 74 años. Mediana de PSA al diagnóstico de CP 23 ng/ml, al inicio TDA 20,2 ng/ml. El 80,2% de pacientes tenían biopsia al diagnóstico del CP: 28,2% grado pronóstico Gleason grupo 1, 38,7% grados 2 y 3 y 33,1% grados 4 y 5. Tratamiento inicial del CP: 75,9% TDA, prostatectomía radical 8,4% y radioterapia 15,1%.De los 952 pacientes, 281 (29,6%) cumplían criterios de CPRC. En este grupo el 21,7% alcanzó PSA indetectable (<0,1 ng/ml) con la TDA 20,2  frente al grupo no CPRC en el que lo alcanzaron el 59,9%. Encontramos mayor probabilidad de progresión a CPRC en pacientes con PSA al diagnóstico de CP >30 ng/ml (p=0,000, OR 2,78), grado pronóstico Gleason grupos 4-5 (p=0,000, OR 2,33) y en aquellos que no alcanzan PSA indetectable tras TDA (p<0,01, OR 3,32) variables que se relacionan con los tiempos de progresión a CPRC y especialmente al estadio metastásico. CONCLUSIONES: Se presenta una serie de pacientes CP avanzado en tratamiento con TDA que muestra heterogeneidad de características y de manejo según práctica clínica habitual. En nuestra serie el PSA elevado al diagnóstico, histología desfavorable y no alcanzar un PSA<0,1 ng/ml tras la TDA se presentan como indicadores de progresión a estadio CPRC.

Hidrocele infectado / Infected hidrocele

No disponible

[Neurofibromas in the urogenital system: Report of two cases and literature review.] / Neurofibromas en el sistema urogenital: presentación de dos casos clínicos y revisión de la bibliografía.

OBJECTIVE: We introduce two cases of a 46 and 66-year-old patient, both diagnosed with pelvic neurofibroma (One located in a seminal vesicle, the other in the bladder). The first patient had been diagnosed with Neurofibromatosis type 1 while the other was diagnosed with a sporadic neurofibroma. METHODS: During a study for lower urinary tract symptoms referred, these patients were diagnosed seminal vesicle and bladder neurofibroma, respectively, using image and histological tests. RESULTS: The histopathological and inmunohistochemical characteristics of these benign tumors gave the definitive diagnosis. CONCLUSIONS: Pelvic neurofibromas are a rare entity in this anatomical location. They can be associated with Neurofibromatosis type 1 or not. We get to their diagnosis by an anatomopathological study. Conservative management is the usual procedure, being mandatory a clinical follow-up that must be coupled with image tests.

Neurofibromas en el sistema urogenital: presentación de dos casos clínicos y revisión de la bibliografía / Neurofibromas in the urogenital system: Report of two cases and literature review

OBJETIVO: Se realizó una revisión bilbiográfica en base a dos casos de pacientes de 46 y 66 años diagnosticados de neurofibromas pélvicos (en vesícula seminal y vejiga), siendo uno de ellos esporádico y otro asociado a Neurofibromatosis tipo 1. MÉTODOS: En el contexto del estudio de los pacientes por síntomas del tracto urinario inferior mediante pruebas de imagen y con el estudio anatomopatológico se llegó al diagnóstico de neurofibroma de vesícula seminal y vejiga respectivamente. RESULTADOS: Las características histopatológicas así como las pruebas inmunohistoquímicas permitieron llegar al diagnóstico de este tumor de comportamiento benigno. CONCLUSIONES: Los neurofibromas pélvicos son una entidad rara en esta localización y que pueden aparecer asociados o no a Neurofibromatosis tipo 1. Su diagnóstico se basa en el estudio anatomopatológico y su tratamiento es conservador, precisando un seguimiento clínico y mediante pruebas de imagen

OBJECTIVE: We introduce two cases of a 46 and 66-year-old patient, both diagnosed with pelvic neurofibroma (One located in a seminal vesicle, the other in the bladder). The first patient had been diagnosed with Neurofibromatosis type 1 while the other was diagnosed with a sporadic neurofibroma. METHODS: During a study for lower urinary tract symptoms referred, these patients were diagnosed seminal vesicle and bladder neurofibroma, respectively, using image and histological tests. RESULTS: The histopathological and inmunohistochemical characteristics of these benign tumors gave the definitive diagnosis. CONCLUSIONS: Pelvic neurofibromas are a rare entity in this anatomical location. They can be associated with Neurofibromatosis type 1 or not. We get to their diagnosis by an anatomopathological study. Conservative management is the usual procedure, being mandatory a clinical follow-up that must be coupled with image tests

[Testicular microlithiasis and testicular cancer]. / Microlitiasis testicular y cáncer de testículo.

OBJECTIVE: To check the possible relationship between testicular microlithiasis and testicular carcinoma in a patient in the one which previously we discovered a sonographic image of this condition. The etiopathogenesis, incidence and attitude are discussed. METHODS: A 23-year-old male with a psychomotor retardation secondary to a chromosomopathy presented with orchitis. Scrotal ultrasound discovered testicular microlithiasis, described as many hyperechoic images. Thirteen months later a testicular cancer was found in a new ultrasound. Radical orchiectomy was performed. Currently the patient is under intense follow-up. RESULTS: The histopathological study showed mature teratoma and intratubular germ cell neoplasm. CONCLUSIONS: The testicular microlithiasis has been related with benign and malignant testicular pathology. However, this presence it is not sufficiently clarified and the urologist's attitude to a patient with testicular microlithiasis but asymptomatic is not enough studied.

Microlitiasis testicular y cáncer de testículo / Testicular microlithiasis and testicular cancer

OBJETIVOS: Revisar la posible relación entre el carcinoma testicular y la microlitiasis testicular, presentando el caso clínico de un paciente con hallazgo casual de imagen ecográfica compatible con esta entidad, y que tras un intervalo de tiempo desarrolló una neoplasia testicular. Se comentan la etiopatogenia, incidencia y actitud a tomar ante la presencia de microlitiasis testicular. MÉTODOS: Varón de 23 años, afecto de retraso psicomotor por cromosomopatía, que consulta por orquiepididimitis. En estudio ecográfico de urgencias, aparte de describir imagen compatible con esta, se aprecian múltiples focos hiperecogénicos en ambos testículos, imagen que define la microlitiasis testicular. En ecografía de seguimiento trece meses mas tarde, con persistencia de dichos focos hiperecoicos, se descubre imagen hipoecogénica compatible con proceso tumoral testicular. Ante dicho hallazgo se decide realizar orquiectomía radical. El paciente se encuentra en programa de seguimiento en estrecha vigilancia clínica. RESULTADOS: En el estudio histopatológico se informa la presencia de teratoma maduro asociado a neoplasia intratubular de células germinales. CONCLUSIONES: Se ha intentado relacionar la presencia de microlitiasis testicular con una amplia variedad de procesos testiculares, tanto benignos como malignos. Sin embargo, el significado real de dicha presencia esta aun por establecer, así como la actitud del urólogo ante su hallazgo casual en un testículo, que por otro lado no presente otras alteraciones significativas (AU)